Promising prostate cancer combo trial halted before results
NCT ID NCT01995058
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested two drugs—cabozantinib and abiraterone—together in 54 men with castration-resistant prostate cancer that had spread to bones. The goal was to see if the combination could delay cancer growth. However, the study was stopped early by the sponsor for business reasons, so no effectiveness data were collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cabozantinib and abiraterone (with prednisone)
What this could lead to
If it had worked, this combination could have slowed cancer progression in men with advanced prostate cancer that has spread to bones.
What could go wrong
The trial was terminated early for business reasons, so no results are available. It is unclear if the combination is safe or effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Scottsdale, Arizona, 85258, United States
-
Study site
Sedona, Arizona, 86336, United States
-
Study site
Tucson, Arizona, 85710, United States
-
Study site
Oxnard, California, 93030, United States
-
Study site
San Diego, California, 92108, United States
-
Study site
Aurora, Colorado, 80012, United States
-
Study site
Aurora, Colorado, 80045, United States
-
Study site
Athens, Georgia, 30607, United States
-
Study site
Atlanta, Georgia, 30318, United States
-
Study site
Peoria, Illinois, 61615, United States
-
Study site
Wichita, Kansas, 67214, United States
-
Study site
Las Vegas, Nevada, 89148, United States
-
Study site
Raleigh, North Carolina, 27607, United States
-
Study site
Tualatin, Oregon, 97062, United States
-
Study site
Charleston, South Carolina, 29414, United States
-
Study site
Greenville, South Carolina, 29605, United States
-
Study site
Myrtle Beach, South Carolina, 29572, United States
-
Study site
Dallas, Texas, 75246, United States
-
Study site
Houston, Texas, 77024, United States
-
Study site
Salt Lake City, Utah, 84112, United States